CD8A and breast carcinoma: For clinical studies, co-administration of Huaier or HQH as adjuvant therapy has been reported to reduce CD8+ T lymphocytes in advanced breast cancer patients (73), pediatric patients with primary nephrotic syndrome (74) and severe Mycoplasma pneumonia (13).